The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Resmed Inc (NYSE: RMD) closed at $246.52 in the last session, down -1.41% from day before closing price of $250.04. In other words, the price has decreased by -$1.41 from its previous closing price. On the day, 0.8 million shares were traded. RMD stock price reached its highest trading level at $251.9416 during the session, while it also had its lowest trading level at $245.97.
Ratios:
We take a closer look at RMD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 25.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.35. For the most recent quarter (mrq), Quick Ratio is recorded 2.13 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on September 18, 2025, initiated with a Buy rating and assigned the stock a target price of $330.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on July 15, 2025, while the target price for the stock was maintained at $294.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 08 ’25 when Farrell Michael J. sold 4,991 shares for $251.41 per share. The transaction valued at 1,254,796 led to the insider holds 466,223 shares of the business.
Farrell Michael J. bought 4,991 shares of RMD for $1,254,796 on Dec 08 ’25. On Dec 03 ’25, another insider, FARRELL PETER C, who serves as the Director of the company, sold 2,000 shares for $251.47 each. As a result, the insider received 502,940 and left with 68,773 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 35983609856 and an Enterprise Value of 35959914496. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.23, and their Forward P/E ratio for the next fiscal year is 20.39. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.84 while its Price-to-Book (P/B) ratio in mrq is 5.88. Its current Enterprise Value per Revenue stands at 6.84 whereas that against EBITDA is 18.551.
Stock Price History:
The Beta on a monthly basis for RMD is 0.87, which has changed by 0.017332554 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, RMD has reached a high of $293.81, while it has fallen to a 52-week low of $199.92. The 50-Day Moving Average of the stock is -4.77%, while the 200-Day Moving Average is calculated to be -2.54%.
Shares Statistics:
According to the various share statistics, RMD traded on average about 1.03M shares per day over the past 3-months and 786120 shares per day over the past 10 days. A total of 145.94M shares are outstanding, with a floating share count of 145.05M. Insiders hold about 0.63% of the company’s shares, while institutions hold 65.91% stake in the company. Shares short for RMD as of 1763078400 were 10647780 with a Short Ratio of 10.33, compared to 1760486400 on 8964374. Therefore, it implies a Short% of Shares Outstanding of 10647780 and a Short% of Float of 8.4.
Dividends & Splits
The forward annual dividend rate for RMD is 2.26, which was 2.19 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.008758599. The stock’s 5-year Average Dividend Yield is 0.83. The current Payout Ratio is 22.30% for RMD, which recently paid a dividend on 2025-11-13 with an ex-dividend date of 2025-11-13. Stock splits for the company last occurred on 2010-08-31 when the company split stock in a 2:1 ratio.
Earnings Estimates
The market rating of Resmed Inc (RMD) is currently shaped by the ongoing analysis conducted by 13.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $2.77, with high estimates of $2.86 and low estimates of $2.69.
Analysts are recommending an EPS of between $11.24 and $10.35 for the fiscal current year, implying an average EPS of $10.9. EPS for the following year is $12.02, with 19.0 analysts recommending between $12.63 and $11.63.
Revenue Estimates
According to 16 analysts,. The current quarter’s revenue is expected to be $1.4B. It ranges from a high estimate of $1.43B to a low estimate of $1.36B. As of. The current estimate, Resmed Inc’s year-ago sales were $1.28BFor the next quarter, 16 analysts are estimating revenue of $1.41B. There is a high estimate of $1.44B for the next quarter, whereas the lowest estimate is $1.39B.
A total of 26 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $5.67B, while the lowest revenue estimate was $5.54B, resulting in an average revenue estimate of $5.6B. In the same quarter a year ago, actual revenue was $5.15BBased on 26 analysts’ estimates, the company’s revenue will be $6.02B in the next fiscal year. The high estimate is $6.17B and the low estimate is $5.91B.
